[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/DOID_289",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/DOID_289"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/drugbank:DB00014"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "zoladex is a gonadotropin releasing hormone gnrh agonist indicated for 1 1 1 2 1 3 1 4 1 5 zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2b t4 stage b2 c carcinoma of the prostate treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy see dosage and administration 2 1 and clinical studies 14 1 zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate see dosage and administration 2 2 clinical studies 14 2 zoladex is indicated for the management of endometriosis including pain relief and reduction of endometriotic lesions for the duration of therapy experience with zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months see dosage and administration 2 3 clinical studies 14 3 zoladex is indicated for use as an endometrial thinning agent prior to endometrial ablation for dysfunctional uterine bleeding see dosage and administration 2 4 clinical studies 14 4 zoladex is indicated for use in the palliative treatment of advanced breast cancer in pre and perimenopausal women the estrogen and progesterone receptor values may help to predict whether zoladex therapy is likely to be beneficial see dosage and administration 2 6 clinical pharmacology 12 1 clinical studies 14 5 the automatic safety feature of the syringe aids in the prevention of needlestick injury"
    } ],
    "https://w3id.org/biolink/vocab/association_type" : [ {
      "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation"
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://w3id.org/um/neurodkg/SymptomaticReliefIndication"
    } ]
  }, {
    "@id" : "https://identifiers.org/drugbank:DB00014",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-06-30T09:02:23.100+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs"
    } ]
  }, {
    "@id" : "http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "CgDM5Ozx+3KBVVChJ7qUFFYRGdJV7YTmWh3P6tqeTvVffxEp3+ZptZiXvnrHs6+p7hal3FI+LxJe7jGRUARpOetDcbTa5kfU9+b+VZvxIloofaUqasp6hUJ6159l3IaRAjfNQQYuObNIWfwtCaQCcKp+TyjZsocBw86Aub0gyso="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI"
    } ]
  } ],
  "@id" : "http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#pubinfo"
} ]